Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) is a zinc-dependent metalloenzyme found in Gram-negative bacteria that catalyzes the committed step in lipid A biosynthesis by removing the acetyl group from UDP-3-O-(R)-3-hydroxymyristoyl-N-acetylglucosamine to produce UDP-3-O-(R)-hydroxymyristoyl-glucosamine and acetate. This reaction is essential for the formation of lipid A, which anchors lipopolysaccharide (LPS) to the outer membrane of Gram-negative bacteria. LpxC is a validated antibacterial target due to its essential role in bacterial cell viability and its absence in mammals. Inhibitors of LpxC disrupt lipid A synthesis, leading to bacterial cell death.
Inhibition of LpxC, leading to disruption of lipid A biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine Deacetylase (LpxC).